Latest Healthcare It News

HealthCo Healthcare & Wellness REIT reports a $1.483 billion portfolio valuation, down 4.3% due to cap rate shifts, while suspending its Q2 distribution to safeguard liquidity amid ongoing hospital asset due diligence.

Adherium Limited is raising up to $4 million through a partially underwritten entitlement offer to expand its US digital health platform and recruit key personnel. The capital raise supports scaling patient onboarding and advancing its FDA-cleared smart inhaler technology.

Rhythm Biosciences has regained NATA accreditation for its geneType laboratory, a key step toward commercialising its ColoSTAT® cancer risk test as an in-house diagnostic.

Cogstate Ltd has upgraded its FY25 financial guidance, projecting a 20-24% revenue increase and nearly doubling profit before tax compared to last year.

Microba Life Sciences Limited has had its trading suspension lifted following a capital raising announcement, signaling renewed market activity for the healthcare company.

Microba Life Sciences announces a $12.5 million equity raise, including a strategic $8.3 million investment from Sonic Healthcare, aiming to fuel growth in the UK and achieve regional break-even by FY26.

Microba Life Sciences has raised $14.5 million to accelerate clinical adoption of its microbiome testing products, while narrowing its FY25 revenue guidance and signing a strategic UK laboratory agreement.

Universal Biosensors has requested a voluntary suspension of its shares on the ASX, pending details of a proposed capital raising. The suspension is expected to last until the end of June or until the announcement is made.

Optiscan Imaging Ltd has entered a five-year exclusive collaboration with Long Grove Pharmaceuticals to jointly develop new clinical applications for the fluorescein drug AK-FLOUR®, supporting US clinical trials and FDA regulatory submissions for Optiscan’s InVue® surgical device.

Alcidion Group Limited has upgraded its full-year EBITDA guidance for FY25, now expecting earnings to exceed $4.5 million, driven by contract expansions, cost discipline, and favorable currency effects.

Proteomics International has launched PromarkerD, a pioneering blood test that predicts diabetic kidney disease years before symptoms, marking its entry into the vast US healthcare market.

Mach7 Technologies has expanded its partnership with a major US radiology marketplace, signing a five-year licence amendment worth A$5 million that extends the contract by three years and adds significant value.